NCT04097756View on ClinicalTrials.gov

A Phase I Study of LX-039 Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 7, 2020

Primary Completion Date

August 8, 2022

Study Completion Date

February 7, 2023

Conditions
Advanced Breast Cancer
Interventions
DRUG

LX-039 tablets

orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, or study termination

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

INDUSTRY

NCT04097756 - A Phase I Study of LX-039 Tablets | Biotech Hunter | Biotech Hunter